Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
Emgality®▼ (galcanezumab): New packaging
Changes to the galcanezumab pre-filled pen carton and packaging materials occurred in August 2020. Slight changes to the carton size, carton closure and the location of the carton graphics were implemented.
The tamper evident seal was removed and replaced by a glue dot.
The orientation of the information contained on the label and Instructions for Use was slightly changed. It might not be noticeable to the user.1
Lock ring position
The lock ring position on the pre-filled pen should be in the locked position when a new carton is first opened and the pre-filled pen is first removed from the carton. There are multiple checks in the manufacturing process to ensure the lock ring is in the locked position during assembly and labeling.1
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: September 30, 2020